^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ITI-1001

    i
    Associations
    News

    Trials

    Company:
    HLB Bio Group
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) (NCT05698199)
    Phase 1
    Immunomic Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    03/26/2024
    Initiation :
    08/21/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    CD8 • CD163 • FOXP3
    |
    ITI-1001